Journal article
Authors list: Braun, J.; Lorenz, H. M.; Mueller-Ladner, U.; Schneider, M.; Schulze-Koops, H.; Specker, Ch.; Strangfeld, A.; Wagner, U.; Doerner, T.
Publication year: 2018
Pages: 81-90
Journal: Zeitschrift für Rheumatologie
Volume number: 77
Issue number: 1
ISSN: 0340-1855
eISSN: 1435-1250
DOI Link: https://doi.org/10.1007/s00393-017-0407-0
Publisher: Springer
Citation Styles
Harvard Citation style: Braun, J., Lorenz, H., Mueller-Ladner, U., Schneider, M., Schulze-Koops, H., Specker, C., et al. (2018) Revised Version of the Statement by the DGRh on Biosimilars - Update 2017, Zeitschrift für Rheumatologie, 77(1), pp. 81-90. https://doi.org/10.1007/s00393-017-0407-0
APA Citation style: Braun, J., Lorenz, H., Mueller-Ladner, U., Schneider, M., Schulze-Koops, H., Specker, C., Strangfeld, A., Wagner, U., & Doerner, T. (2018). Revised Version of the Statement by the DGRh on Biosimilars - Update 2017. Zeitschrift für Rheumatologie. 77(1), 81-90. https://doi.org/10.1007/s00393-017-0407-0
Keywords
ANKYLOSING-SPONDYLITIS; CT-P13; DOUBLE-BLIND; inflammatory arthritis; INNOVATOR INFLIXIMAB; ORIGINATOR INFLIXIMAB; PARALLEL-GROUP; RHEUMATOID-ARTHRITIS
